发明名称 METHOD FOR PROGNOSIS OF THE EFFICACY OF ORAL IMMUNOTHERAPY FOR THE TREATMENT OF ALLERGY TO PROTEINS IN COW'S MILK
摘要 The present invention relates to a method for prognosis of the efficacy of oral immunotherapy for the treatment of allergy to proteins in cow's milk providing a solution to the problems stated in the state of the art since it provides a method which allows making a prognosis of the number of reactions that will be produced during oral immunotherapy (OIT) against proteins in cow's milk and/or an estimate of the treatment time required to achieve tolerance or desensitization during OIT against proteins in cow's milk and/or the need for pre-medication during OIT in a human subject.
申请公布号 US2016169907(A1) 申请公布日期 2016.06.16
申请号 US201414908723 申请日期 2014.08.01
申请人 Fundación para la Investigación Biomédica del Hospital Universitario ;Fundación para la Investigación Biomédica del Hospital Clinico San Carlos 发明人 De La Hoz Caballer Mª Belén;Martínez Botas Javier;Cerecedo Carballo Inmaculada;Fernández Rivas Montserrat;Rodríguez Álvarez Mónica
分类号 G01N33/68 主分类号 G01N33/68
代理机构 代理人
主权项 1. A method for prognosis of the number of reactions during oral immunotherapy (OIT) against proteins in cow's milk and/or an estimate of the treatment time required to achieve tolerance or desensitization during OIT against proteins in cow's milk and/or the need for pre-medication during OIT in a human subject, comprising the following steps: c. Isolating a biological sample from the subject; d. Determining the presence or absence of IgE antibodies in the biological sample of step a) against or with specificity for peptides identified with the following sequences: a. At least one sequence selected from the group consisting of peptide sequences SEQ ID NO: 1-4 and/or fragments thereof selected from the list consisting of sequences SEQ ID NO: 18-32 and/or derivatives of sequences SEQ ID NO: 18-32 that are immunologically active; and/orb. At least one sequence selected from the group consisting of peptide sequences SEQ ID NO: 5-8 and/or fragments thereof selected from the list consisting of sequences SEQ ID NO: 33-45 and/or derivatives of sequences SEQ ID NO: 33-45 that are immunologically active; and/orc. At least one sequence selected from the group consisting of peptide sequences SEQ ID NO: 9-13 and/or fragments thereof selected from the list consisting of sequences SEQ ID NO: 46-63 and/or derivatives of sequences SEQ ID NO: 46-63 that are immunologically active; and/ord. At least one sequence selected from the group consisting of peptide sequences SEQ ID NO: 14-15 and/or fragments thereof selected from the list consisting of sequences SEQ ID NO: 64-69 and/or derivatives of sequences SEQ ID NO: 64-69 that are immunologically active; and/ore. At least one sequence selected from the group consisting of peptide sequences SEQ ID NO: 16-17 and/or fragments thereof selected from the list consisting of sequences SEQ ID NO: 70-75 and/or derivatives of sequences SEQ ID NO: 70-75 that are immunologically active; where the prognosis of the number of reactions during oral immunotherapy (OIT) against proteins in cow's milk and/or an estimate of the treatment time required to achieve tolerance or desensitization during OIT against proteins in cow's milk and/or the need for pre-medication during OIT is established by correlating the number of peptide sequences recognized by IgE antibodies in the samples from the subjects before starting OIT treatment (time 0) with reference values established based on those same peptide sequences which correlate the number of peptides recognized by IgE antibodies in the samples from the patients with the response after OIT treatment.
地址 Madrid ES